15469-78-0

Basic information

• Product Name: 3-hydroxydecanoic acid N-acetylcysteamine thioester
• Synonyms: 3-hydroxydecanoic acid N-acetylcysteamine thioester
• CAS NO: 15469-78-0
• Molecular Formula: C14H27 N O3 S
• Molecular Weight: 289.43
• Mol File: 15469-78-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 469.3°Cat760mmHg
• Flash Point: 237.6°C
• Appearance: /
• Density: 1.054g/cm³
• Vapor Pressure: 8.83E-11mmHg at 25°C
• Refractive Index: 1.494
• CAS DataBase Reference: 3-hydroxydecanoic acid N-acetylcysteamine thioester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxydecanoic acid N-acetylcysteamine thioester(15469-78-0)
• EPA Substance Registry System: 3-hydroxydecanoic acid N-acetylcysteamine thioester(15469-78-0)

Safety Data

• Hazardous Substances Data: 15469-78-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H27NO3S/c1-3-4-5-6-7-8-13(17)11-14(18)19-10-9-15-12(2)16/h13,17H,3-11H2,1-2H3,(H,15,16)

Upstream product

• 5561-87-5 3-hydroxydecanoic acid 
• 1190-73-4 2-(acetylamino)ethanethiol 
• 111-64-8 n-octanoic acid chloride 
• 22348-96-5 methyl 3-oxodecanoate 
• 62675-82-5 methyl 3-hydroxydecanoate 
• 1341177-73-8 β-ketodecanoyl-N-acetylcysteamine thioester 

Relevant articles and documents

A FabG inhibitor targeting an allosteric binding site inhibits several orthologs from Gram-negative ESKAPE pathogens

The spread of antibiotic resistance within the ESKAPE group of human pathogenic bacteria poses severe challenges in the treatment of infections and maintenance of safe hospital environments. This motivates efforts to validate novel target proteins within these species that could be pursued as potential targets for antibiotic development. Genetic data suggest that the enzyme FabG, which is part of the bacterial fatty acid biosynthetic system FAS-II, is essential in several ESKAPE pathogens. FabG catalyzes the NADPH dependent reduction of 3-keto-acyl-ACP during fatty acid elongation, thus enabling lipid supply for production and maintenance of the cell envelope. Here we report on small-molecule screening on the FabG enzymes from A. baumannii and S. typhimurium to identify a set of μM inhibitors, with the most potent representative (1) demonstrating activity against six FabG-orthologues. A co-crystal structure with FabG from A. baumannii (PDB:6T65) confirms inhibitor binding at an allosteric site located in the subunit interface, as previously demonstrated for other sub-μM inhibitors of FabG from P. aeruginosa. We show that inhibitor binding distorts the oligomerization interface in the FabG tetramer and displaces crucial residues involved in the interaction with the co-substrate NADPH. These observations suggest a conserved allosteric site across the FabG family, which can be potentially targeted for interference with fatty acid biosynthesis in clinically relevant ESKAPE pathogens.

Characterization of FabG and FabI of the Streptomyces coelicolor dissociated fatty acid synthase

Streptomyces coelicolor produces fatty acids for both primary metabolism and for biosynthesis of the secondary metabolite undecylprodiginine. The first and last reductive steps during the chain elongation cycle of fatty acid biosynthesis are catalyzed by FabG and FabI. The S. coelicolor genome sequence has one fabI gene (SCO1814) and three likely fabG genes (SCO1815, SCO1345, and SCO1846). We report the expression, purification, and characterization of the corresponding gene products. Kinetic analyses revealed that all three FabGs and FabI are capable of utilizing both straight and branched-chain β-ketoacyl-NAC and enoyl-NAC substrates, respectively. Furthermore, only SCO1345 differentiates between ACPs from both biosynthetic pathways. The data presented provide the first experimental evidence that SCO1815, SCO1346, and SCO1814 have the catalytic capability to process intermediates in both fatty acid and undecylprodiginine biosynthesis.